Kit Box Character Contest  Make your EpiGentek box “alive” and win a $1500 grant for antibodies plus more! » Learn More
Epigentek Home
 
EpiGentek Guarantee

GLIPR1 Polyclonal Antibody

Share:

Write a Review
Immunofluorescent analysis of HepG2 cells at a dilution of 1:100 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L)
Application: ELISA, IF, IHC
Areas of Research: Apoptosis & Cell Death, Cell Cycle
Clonality: Polyclonal
Conjugate: Unconjugated
Host: Rabbit
Isotype: IgG
Purification: Protein G Purified
Reactivity: Human
Trial Size Available: Yes
100% Guarantee: 6 months
Catalog No.SizePriceQty
A52864-02020 µg $99.00 
A52864-05050 µg $256.00 
A52864-100100 µg $359.00 
Order now & get it by Wednesday, September 4th  
Product Overview

Background
Glioma pathogenesis-related protein 1 (GLIPR1) regulated numerous apoptotic, cell cycle, and spindle/centrosome assembly-related genes, including AURKA and TPX2, and induced apoptosis and/or mitotic catastrophe (MC) in prostate cancer (PCa) cells, including p53-mutated/deleted, androgen-insensitive metastatic PCa cells.

Description
GLIPR1 Polyclonal Antibody. Unconjugated. Raised in: Rabbit.

Formulation
Liquid. 0.03% Proclin 300, 50% Glycerol, 0.01M PBS, PH 7.4.

Specificity
Human

Isotype
IgG

Uniprot ID
P48060

Purification
>95%, Protein G purified

Immunogen
Recombinant Human Glioma pathogenesis-related protein 1 protein (22-232AA)

Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C (short-term) or -80°C (long-term). Avoid repeated freeze.

Alternative Names
Protein RTVP-1, GLIPR1, GLIPR, RTVP1

Application
ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200

User Guide & MSDS

[User Guide]*
*Always use the actual User Guide that shipped with your product. Is the above file locked? You can also request user guides by emailing info@epigentek.com along with your contact information and institution name.

Kit Box Contest
Related Products
Terms & Conditions | Privacy Policy | Site Map
Copyright © 2019 EpiGentek Group Inc. All rights reserved.